Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Research & Development (2021 - 2026)

HeartSciences filings provide 6 years of Research & Development readings, the most recent being $638575.0 for Q1 2026.

  • On a quarterly basis, Research & Development fell 38.19% to $638575.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $3.3 million, a 26.9% decrease, with the full-year FY2025 number at $4.4 million, up 52.37% from a year prior.
  • Research & Development hit $638575.0 in Q1 2026 for HeartSciences, down from $727026.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.4 million in Q2 2022 to a low of $434198.0 in Q3 2022.
  • Median Research & Development over the past 5 years was $757303.0 (2023), compared with a mean of $831939.9.
  • Biggest five-year swings in Research & Development: tumbled 60.58% in 2023 and later skyrocketed 116.56% in 2024.
  • HeartSciences' Research & Development stood at $848976.0 in 2022, then dropped by 10.8% to $757303.0 in 2023, then surged by 58.32% to $1.2 million in 2024, then plummeted by 39.36% to $727026.0 in 2025, then fell by 12.17% to $638575.0 in 2026.
  • The last three reported values for Research & Development were $638575.0 (Q1 2026), $727026.0 (Q4 2025), and $997206.0 (Q3 2025) per Business Quant data.